Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152097 · ClinicalTrials.gov registry record · NA
Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT03152097 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 13 participants.
The verdict
NCT03152097, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The project will investigate the modulation of flavin-containing monooxygenase (FMO) formation of the CVD risk factor trimethylamine-N-oxide (TMAO) in patients with kidney disease.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Commercially available Diindolylmethane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2019-08-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03152097
The ClinicalTrials.gov registry entry for NCT03152097 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03152097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03152097 about?
NCT03152097 is a clinical study titled "Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study". The project will investigate the modulation of flavin-containing monooxygenase (FMO) formation of the CVD risk factor trimethylamine-N-oxide (TMAO) in patients with kidney disease.
What is the current status of trial NCT03152097?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2018-03-30. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT03152097?
The interventions under investigation include: Placebo (OTHER), Commercially available Diindolylmethane (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03152097?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.